ImmunoCellular Therapeutics, Ltd. | 2013 | FY | 3


Development Stage Enterprise—The Company is a development stage enterprise and is devoting substantially all our present efforts to research and development. All losses accumulated since inception are considered part of the Company’s development stage activities.


us-gaap:DevelopmentStageEnterpriseGeneralDisclosuresTextBlock